Menu
image description

Category: LupusTrials.org

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

NEW YORK, N.Y. — October 17, 2023: Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced a partnership with Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing the engineered natural killer (NK) cell therapy NKX019 for refractory lupus nephritis that has not responded to standard treatment. Lupus Therapeutics has provided advisory […] Read More

Lupus Therapeutics PALS Program Expansion

October 1, 2023 Call for Individuals to Serve as a Trained Peer Educator Lupus Therapeutics, the clinical affiliate of Lupus Research Alliance, is pleased to announce the expansion of the highly successful Patient Advocates for Lupus Studies (PALS) pilot program with an exciting request for people who have clinical trial experience as well as a […] Read More

LRA Highlights Groundbreaking Lupus Research at ACR Convergence 2023

This information is brought to you by the Lupus Research Alliance and Lupus Therapeutics and is not sponsored by, nor a part of, the American College of Rheumatology.  30+ presentations of studies funded by the LRA spanning a broad spectrum of research areas Positive results from Phase 2/3 clinical studies supported by LRA affiliate Lupus Therapeutics point to […] Read More

Rinvoq Advances to Phase 3 in Lupus

March 27, 2023 Based on positive results of a Phase 2 clinical trial testing upadacitinib (Rinvoq®) given alone or with elsubrutinib once daily for moderate to severe systemic lupus erythematosus, developer AbbVie is advancing the drug to a Phase 3 trial. The trial also showed that steroid dose either went down or stayed the same […] Read More

Investigational CAR T Cell Gets Fast Tracked by U.S. FDA

May 1, 2023 The LRA and our clinical arm Lupus Therapeutics are pleased to share good news from Cabaletta Bio, Inc. that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CABA-201, a CAR T cell investigational therapy in development to treat systemic lupus erythematosus and lupus nephritis – a common […] Read More

Lupus Research Alliance and its Clinical Research Affiliate Lupus Therapeutics Launch the Lupus Landmark Study to Accelerate Personalized Treatments in Lupus

The Lupus Landmark Study, the largest prospective observational study in lupus, will enroll 3,500 patients throughout North America over five years The Lupus Landmark Study is a key component of the Lupus Nexus, a first-of–its-kind in lupus registry, biorepository and data/knowledge portal NEW YORK, NY. May 23, 2023 – The Lupus Research Alliance and its clinical […] Read More

Lupus Therapeutics Partners with AbbVie on Clinical Trial Recruitment Efforts in SLE Through LuCIN Lupus Clinical Trial Network 

NEW YORK, N.Y., Oct. 24, 2023 – Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announces a partnership with AbbVie Inc. for the Phase 3 clinical program of upadacitinib (RINVOQ®) in individuals living with systemic lupus erythematosus (SLE). In this partnership, Lupus Therapeutics will assist with study participant recruitment, site activation and […] Read More

Summary Highlights of Important Research Presented at ACR Convergence 2023

November, 2023 At the recent ACR Convergence 2023, the annual meeting of the American College of Rheumatology, important lupus clinical trial data and breakthrough foundational research were presented. Following are highlights of work funded by the Lupus Research Alliance or supported in partnership with industry through our clinical affiliate Lupus Therapeutics. CAR-T Cell Therapy is […] Read More

Study Reported Telitacicept Showed Favorable Effectiveness and Safety for SLE

Dec. 1, 2023 A new paper published in Lupus Science & Medicine on the results of a study in China reported that a potential treatment telitacicept demonstrated favorable effectiveness and safety in patients with active SLE. It also improved effects of lupus on kidneys and the blood. Telitacicept is conditionally approved in China as a […] Read More